Cover Image
市場調查報告書

克隆氏症診斷及治療的全球市場:成長,趨勢與預測(2017年∼2022年)

Global Crohn's Disease Diagnostic and Therapeutic Market - Segmented by Type of Disease, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 391371
出版日期 內容資訊 英文 105 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
克隆氏症診斷及治療的全球市場:成長,趨勢與預測(2017年∼2022年) Global Crohn's Disease Diagnostic and Therapeutic Market - Segmented by Type of Disease, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日期: 2018年05月01日 內容資訊: 英文 105 Pages
簡介

克隆氏症(CD)是一種炎症性腸病(IBD),影響從口腔到肛門的胃腸道的任何部分。由於遺傳易感人群中的環境因素,免疫因素和細菌因素共同造成的。據亞特蘭大CDS估計,每10萬人中約有200人受到影響,發病率為每10萬人每年3.1至14.6人。

本報告提供全球克隆氏症診斷及治療市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

第1章 簡介

  • 調查的成果
  • 市場定義
  • 數量單位
  • 基本貨幣
  • 檢討與預測期間
  • 一般調查的前提條件

第2章 調查方法

  • 簡介
  • 分析方法論
  • 計量預測模式
  • 調查的前提條件

第3章 摘要整理

第4章 關鍵問題

第5章 市場概況及產業的趨勢

  • 目前市場方案
  • 技術概要
  • 治療藥新的發展
  • 投資分析
  • 波特的五力分析
    • 供應商談判力
    • 買主談判力
    • 競爭程度
    • 替代品的威脅
    • 新加入廠商的威脅

第6章 成長要素,阻礙因素,機會及課題分析(DROC)

  • 市場成長要素
    • 這個疾病相關的複數的症狀,必須在個別治療上注意
    • 迅速的診斷的要求
    • 受影響人口隨著時間而增加
  • 市場阻礙因素
    • 市場上沒有可取得的特定治療藥
    • 人們的意識缺乏及與其他腸胃疾病的症狀相似性
    • 缺乏成本效果高的治療方法
  • 市場機會
    • 生物相似藥的出現
    • 抗TNF市售品牌Remicade和Humira等各種有用藥物的專利到期

新參與市場企業的大門

  • 主要課題

第7章 全球克隆氏症診斷及治療市場

  • 回結腸炎
  • 髂骨炎
  • 胃十二指腸的克隆氏症
  • 空腸回腸炎
  • 克隆結腸炎

第8章 全球克隆氏症的診斷及治療市場:各診斷方法

  • 血液檢驗
  • 糞便檢驗
  • 大腸內視鏡檢驗
  • 彈性S狀結腸鏡檢驗
  • 電腦斷層攝影
  • 磁振造影
  • 膠囊內視鏡
  • 雙球囊內視鏡檢驗

第9章 克隆氏症的診斷及治療市場:各治療法

  • 藥、投藥
    • 發炎治療藥
    • 免疫抑劑
    • 止痛藥
  • 手術

第10章 全球克隆氏症診斷及治療市場:各地區(市場佔有率與預測)

  • 北美
    • 簡介
    • 美國
    • 加拿大
    • 其他
  • 歐洲
    • 簡介
    • 法國
    • 英國
    • 德國
    • 西班牙
    • 俄羅斯
    • 義大利
    • 其他
  • 亞太地區
    • 簡介
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 其他
  • 中東、非洲
    • 簡介
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 以色列
    • 其他MEA各國
  • 中南美
    • 簡介
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他

第11章 競爭情形

第12章 主要供應商

  • Abbvie
  • Celgene Corportation
  • Genetech
  • Janssen Biotech Inc.
  • Pfizer Inc.
  • Prometheus Laboratories Inc.
  • Salix Pharmaceuticals Inc.
  • 武田藥品工業
  • Johnnson and Johnnson

第13章 投資機會的分析師預期

第14章 市場未來展望

第8章 附錄

  • 簡稱
  • 參考文獻
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 50777

The global Crohn's disease diagnostic and therapeutic market is estimated to grow at a good CAGR during the forecast period. Crohn's disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals.

Affected Population Increasing with Time

It is estimated that around 1.6 million Americans have the inflammatory bowel disease (IBD). This number includes about 780,000 population are having Crohn's disease, and another 907,000 people are with ulcerative colitis. Research suggests that about six to 15 new cases of Crohn's disease are diagnosed per 100,000 people each year. People are most frequently diagnosed with Crohn's disease and ulcerative colitis in the late adolescence or in early adulthood, even though the diagnosis may happen at any age. Many population-based research studies have shown that Crohn's disease is somewhat more common in women than men, while ulcerative colitis is slightly more common in men than women. As the prevalence of the disease increases, it is expected to drive the Crohn's disease diagnostic and therapeutic market.

Also, the increasing demand for prompt diagnosis and multiple symptoms associated with the disease requiring individual therapeutic attention, are increasing the growth of the market.

Lack of a Cost-effective Treatment

Current costs for the treatment and diagnosis of Crohn's disease is high, due to the availability of several new therapeutic drugs and changes in the surgical treatment of the disease. For example, the total cost of Crohn's disease in the United States is around USD 3.6 billion every year, and the average yearly medical cost per patient is about USD 8,265, with more than one-third of that cost being medications. Biologic medications or drugs are usually expensive. Hospitalization accounted for 31.4% of the cost. On an average, people who have to be hospitalized for Crohn's disease are expected to spend about 5.8 days in the hospital. All these treatment cost issues are hindering the Crohn's diagnostic and therapeutic market. Also, as no specific treatment or drug is available in the market, and there is lack of awareness among the people coupled with symptom similarity with other gastrointestinal disease are hindering the market growth.

North America to Lead the Market

North America is dominating the Crohn's disease diagnostic and therapeutic market due to the increasing prevalence of Crohn's disease in the region. Asia-Pacific is expected to record a substantial growth in the forecast period.

Key Developments in the Market:

  • February 2018: AbbVie announced New Phase II data for Upadacitinib showing the clinical and endoscopic outcomes in Crohn's disease at 52 weeks.
  • Major Players: ABBVIE, CELGENE CORPORATION, GENENTECH, JANSSEN BIOTECH INC., PFIZER INC., PROMETHEUS LABORATORIES, INC. (NESTLE), SALIX PHARMACEUTICALS, INC. (VALEANT PHARMACEUTICALS), TAKEDA'S PHARMACEUTICAL LTD, and JOHNSON & JOHNSON, among others.

Reasons to Purchase the Report:

  • Follow the current and future global Crohn's disease diagnostic and therapeutic market in the developed and emerging markets.
  • Analyzing various perspectives of the market with the help of Porter's
  • Five Forces Analysis.
  • Identify the segment that is expected to dominate the market.
  • Identify the regions that are expected to witness the fastest growth during the forecast period.
  • Identify the latest developments, market shares, and strategies employed by the major market players.
  • 3-month analyst support along with the Market Estimate sheet (in Excel).

Customization of the Report:

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threats of New Entrants
    • 5.2.4 Threat of Substitute Products and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Drivers
    • 6.1.1 Multiple Symptoms Associated with the Disease Requiring Individual Therapeutic Attention
    • 6.1.2 Demand for Prompt Diagnosis
    • 6.1.3 Affected Population Increasing with Time
  • 6.2 Restraints
    • 6.2.1 No Specific Treatment or Drug Available in the Market
    • 6.2.2 Lack of Awareness among the People and Symptom Similarity with Other Gastrointestinal Disease
    • 6.2.3 Lack of a Cost Effective Treatment
  • 6.3 Opportunities
    • 6.3.1 Emergence of Biosimilars
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Disease
    • 7.1.1 Ileocolitis
    • 7.1.2 Iletis
    • 7.1.3 Gastroduodenal Crohn'S
    • 7.1.4 Jejunoileitis
    • 7.1.5 Crohn's Colitis
  • 7.2 By Diagnosis
    • 7.2.1 Blood Tests
    • 7.2.2 Fecal Test
    • 7.2.3 Colonoscopy
    • 7.2.4 Flexible Sigmoidoscopy
    • 7.2.5 Computerized Tomography
    • 7.2.6 Magnetic Resonance Imaging
    • 7.2.7 Capsule Endoscopy
    • 7.2.8 Others
  • 7.3 By Treatment
    • 7.3.1 Medication
      • 7.3.1.1 Medication for Inflammation
      • 7.3.1.2 Medication for Immunosuppression
      • 7.3.1.3 Medication for Pain Relief
    • 7.3.2 Surgery
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States
      • 7.4.1.2 Canada
      • 7.4.1.3 Mexico
    • 7.4.2 Europe
      • 7.4.2.1 France
      • 7.4.2.2 Germany
      • 7.4.2.3 United Kingdom
      • 7.4.2.4 Italy
      • 7.4.2.5 Spain
      • 7.4.2.6 Rest of Europe
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China
      • 7.4.3.2 Japan
      • 7.4.3.3 India
      • 7.4.3.4 Australia & New Zealand
      • 7.4.3.5 South Korea
      • 7.4.3.6 Rest of Asia-Pacific
    • 7.4.4 Middle East & Africa
      • 7.4.4.1 GCC
      • 7.4.4.2 South Africa
      • 7.4.4.3 Rest of the Middle East & Africa
    • 7.4.5 South America
      • 7.4.5.1 Brazil
      • 7.4.5.2 Argentina
      • 7.4.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Abbvie
  • 9.2 Celgene Corporation
  • 9.3 Genetech
  • 9.4 Janssen Biotech Inc.
  • 9.5 Johnson & Johnson
  • 9.6 Pfizer Inc.
  • 9.7 Prometheus Laboratories Inc. (Nestle)
  • 9.8 Salix Pharmaceuticals Inc. (Valeant Pharmaceuticals)
  • 9.9 Takeda's Pharmaceutical Ltd

List not Exhaustive

10. Future of the Market

11. Disclaimer

Back to Top